After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising concerns over future vaccine access. The US Food and Drug Administration (FDA) has given full approval to Novavax’s Covid-19 vaccine,